FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * MISRA TUSHAR 2. Issuer Name and Ticker or Trading Symbol Mersana Therapeutics, Inc. [ MRSN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Manufacturing Officer
(Last)         (First)         (Middle)
C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
8/16/2021
(Street)
CAMBRIDGE, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $11.56  8/16/2021    A     112500       (1) 8/15/2031  Common Stock  112500  $0  112500  D   
Restricted stock unit   (2) 8/16/2021    A     25000       (3)  (3) Common Stock  25000  $0  25000  D   

Explanation of Responses:
(1)  The options will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years.
(2)  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.
(3)  The restricted stock units will vest in equal annual installments over the first four years after the vesting commencement date, August 16, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MISRA TUSHAR
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139


Chief Manufacturing Officer

Signatures
Brian DeSchuytner, as Attorney-in-Fact 8/18/2021
**Signature of Reporting Person Date
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Mersana Therapeutics Charts.
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Mersana Therapeutics Charts.